



COPY OF PAPERS
ORIGINALLY FILED

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1600

PATENT
Attorney Docket No. 201895

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Falck-Pedersen

Application No. 08/653,114

Filed: May 24, 1996

For: ADENOVIRUS GENE EXPRESSION
SYSTEM

Art Unit: 1632

Examiner: R. Schnizer

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

RESPONSE TO OFFICE ACTION

Commissioner for Patents
Box AF
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated March 15, 2002, please enter the following amendments and consider the following remarks.

AMENDMENTS

Please amend claims 1 and 20 to read as follows:

I

1. (Four Times Amended) An adenoviral vector for expressing a heterologous gene(s) in a host cell, comprising at least one insertion site for cloning a selected heterologous gene, and, in an orientation opposite to the direction of transcription of the adenoviral region into which it is inserted, (a) a heterologous promoter positioned upstream from said at least one insertion site, wherein, upon cloning of the selected heterologous gene into said at least one insertion site, said gene is under the regulatory control of said heterologous promoter; (b) a eukaryotic splice acceptor and splice donor site positioned downstream of said promoter and upstream of said at least one insertion site; and (c) a polyadenylation sequence positioned downstream of said insertion site.